11
February 14th 2025
Article
Obesity is a significant global health challenge that requires lifestyle changes and
effective pharmacological treatments to overcome. Human glucagon-like peptide 1
(GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity
treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking
advance in obesity treatment, offering greater patient comfort and adherence to
expand the therapeutic market.